Gilead Sciences, Inc. - Common Stock · Transaction Jan 27, 2026 · Filed Feb 26, 2026 · $1,001 to $15,000
XNAS · GILD
Quote not reported
Gilead Sciences Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Not reported
Follow $GILD
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $GILD by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredTue Oct 13 · last completed session · daily score · 18h old · GILD
MethodologyGILD
Gilead Sciences Inc
Tue Oct 13 · last completed session · daily score · 18h old
Upper range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
63/ 100
Veridion Score
Upper range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Confidence: HIGH · 6 of 6 factors measured · Tue Oct 13 · last completed session · daily score · 18h old
AI Analysis
SovereignWhy is GILD moving today?
Sovereign unlock connects news, insider activity, analyst moves, and available price action.
About Gilead Sciences Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Listed since
1992
Employees
17K
Country
US
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Market cap
$183.4B
P/E
21.71×
EPS
$-2.6551
Shares out
1.2B
GILD overview
Related filings and maps
Public disclosures
Congress activity in GILD
40 filers · 66 buys · 54 sells (5 labeled S (partial)) · Feb 6, 2014 to May 6, 2026 · House 89 / Senate 31
All available history · Latest 5 of 120 lines · Read Oct 14, 2026, 3:01 PM UTC
Official filing ↗
Gilead Sciences, Inc. - Common Stock · Transaction Sep 23, 2025 · Filed Oct 10, 2025 · $1,001 to $15,000
Gilead Sciences, Inc. - Common Stock · Transaction Jun 6, 2025 · Filed Jun 18, 2025 · $1,001 to $15,000
Gilead Sciences, Inc. - Common Stock · Transaction May 14, 2025 · Filed Jun 11, 2025 · $1,001 to $15,000
Jefferson ShreveSell
Gilead Sciences, Inc. - Common Stock · Transaction May 12, 2025 · Filed Jun 22, 2025 · $15,001 to $50,000
Federal contracts
GILD contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for GILD in this window.
Lobbying spend
GILD lobbying filings, year to date.
Registered lobbying filings matched to Gilead Sciences Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for GILD in this window.
Analyst ratings
Sovereign unlock shows available analyst consensus for GILD.